Indirubin alleviates CCl۴-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways
Publish place: Iranian Journal of Basic Medical Sciences، Vol: 26، Issue: 9
Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 62
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJBMS-26-9_008
تاریخ نمایه سازی: 5 شهریور 1402
Abstract:
Objective(s): Liver fibrosis is a common liver disease caused by chronic liver damage. However, there are currently no approved drugs available to treat it. Therefore, the therapeutic effect of indirubin on liver fibrosis was evaluated. This study investigated the protective effect and related molecular mechanism of indirubin against CCl۴-induced liver fibrosis in mice.Materials and Methods: We first detected the effect of indirubin on liver fibrosis in mice (n=۸ per group, ۳۲ mice total) by ELISA, HE, and Masson staining. Subsequently, the proliferation of activated HSCs was detected by MTT and EdU. Finally, the changes of related proteins and signaling pathways in mice treated with indirubin were investigated by qRT-PCR and Western blot. One-way ANOVA or two-tailed student’s t-test was used for comparison between groups.Results: Firstly, we found that indirubin (۲۵ mg/kg) therapy could attenuate liver injury and significantly down-regulate α-SMA (P=۰.۰۰۳۸) and collagen ۱ (P=۰.۰۰۵۷) in the liver using CCl۴-induced liver fibrosis in mice. Secondly, we showed that indirubin (۲۵ μM) could significantly inhibit hepatic stellate cell (HSC) trans-differentiation into myofibroblasts and proliferation (P=۰.۰۰۶۳) in HSC-T۶ cells treated by TGF-β. Finally, we showed that indirubin could greatly reduce the protein levels of p-Smad۲/۳, p۳۸, p-ERK, and p-JNK in vivo and in vitro.Conclusion: Our results suggested that indirubin alleviated liver fibrosis and HSC activation mainly through TGF-β-mediated signaling pathways in vivo and in vitro. In conclusion, our data showed that indirubin could be a promising clinical therapeutic drug for the prevention and treatment of liver fibrosis.
Authors
Xiaoying Li
College of Biology and Food Engineering, Huaihua University. Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Hunan, ۴۱۸۰۰۰, China
Yuanzhi Yao
College of Biology and Food Engineering, Huaihua University. Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Hunan, ۴۱۸۰۰۰, China
Lin Wei
College of Biology and Food Engineering, Huaihua University. Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Hunan, ۴۱۸۰۰۰, China
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :